Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 1;109(6):1629-1638.
doi: 10.1097/JS9.0000000000000336.

The impact of surgery and survival prediction in patients with gastroenteropancreatic neuroendocrine tumors: a population-based cohort study

Zenghong Wu  1 , Weijun Wang, Kun Zhang, Mengke Fan, Rong Lin
Affiliations

The impact of surgery and survival prediction in patients with gastroenteropancreatic neuroendocrine tumors: a population-based cohort study

Zenghong Wu et al. Int J Surg. .

Abstract

Objective: This study aimed at assessing the impact of surgical treatments in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Methods: A propensity score-matched analysis based on data in the Surveillance, Epidemiology, and End Results database was used to assess the efficacy of surgical treatment in patients with GEP-NETs.

Results: A total of 7515 patients diagnosed with GEP-NETs from 2004 to 2015 were evaluated from the Surveillance, Epidemiology, and End Results database. There were 1483 patients in the surgery group and 6032 patients in the nonsurgery group. Compared with patients in the surgery group, patients in the nonsurgery group were inclined to receive chemotherapy (50.8 vs. 16.7%) and radiation (12.9 vs. 3.7%) as treatment options. Multivariate Cox regression analysis revealed higher rates of overall survival (OS) outcomes for GEP-NETs patients who had been subjected to surgery (hazard ratio=0.483, 95% CI=0.439-0.533, P <0.001). Then, to reduce the impact of bias, a 1 : 1 propensity score-matched analysis was performed for the two groups of patients. A total of 1760 patients were assessed and each subgroup included 880 patients. In the matched population, the patients exhibited the ability to significantly benefit from surgery (hazard ratio=0.455, 95% CI=0.439-0.533, P <0.001). The OS outcomes for radiation or chemotherapy patients who had been treated with surgery were better than those of patients who had not been treated with surgery ( P <0.001). In addition, it was found that the OS of patients was not significant after rectum and small intestine surgery, whereas there was a significant difference in OS after colon, pancreas, and stomach surgery on the patients. Patients who had been subjected to surgery in the rectum and small intestines exhibited better therapeutic benefits.

Conclusion: Patients with GEP-NETs who are treated with surgery have better OS outcomes. Therefore, surgery is recommended for specified selected patients with metastatic GEP-NETs.

PubMed Disclaimer

Conflict of interest statement

The authors have no potential conflicts of interest to disclose.

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

Figures

Figure 1
Figure 1
Overall survival analysis of GEP-NETs patients in different stages and grades. A. Stage I; B. Stage II; C. Stage III; D, Stage IV; E. Grade I; F. Grade II; G, Grade III; H. Grade IV.
Figure 1
Figure 1
Overall survival analysis of GEP-NETs patients in different stages and grades. A. Stage I; B. Stage II; C. Stage III; D, Stage IV; E. Grade I; F. Grade II; G, Grade III; H. Grade IV.
Figure 2
Figure 2
Overall survival analysis of GEP-NETs patients in different subgroups. A. Radiation; B. Chemotherapy; C. Metastasis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Xu JX, Wu DH, Ying LW, et al. . Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: a new category in the World Health Organization classification. World J Gastroenterol 2021;27:8123–8137. - PMC - PubMed
    1. Dasari A, Shen C, Halperin D, et al. . Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017;3:1335–1342. - PMC - PubMed
    1. Zhong Q, Chen QY, Xie JW, et al. . Incidence trend and conditional survival estimates of gastroenteropancreatic neuroendocrine tumors: a large population-based study. Cancer Med 2018;7:3521–3533. - PMC - PubMed
    1. Fernandes CJ, Leung G, Eads JR, et al. . Gastroenteropancreatic neuroendocrine tumors. Gastroenterol Clin North Am 2022;51:625–647. - PubMed
    1. Kole C, Charalampakis N, Vailas M, et al. . Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NETs): a 2021 update. Cancer Immunol Immunother 2022;71:761–768. - PMC - PubMed

Supplementary concepts